Cayman Chemical Company, Inc. (Cayman) develops and manufactures chemical compounds for research use only (RUO) and has a separate business division that produces small molecules as Active Pharmaceutical Ingredients (API) for human and veterinary use.

RUO-grade products, such as Cayman’s SM-102 (Item # 33474), are intended only for in vitro or animal (exploratory or preclinical) use. In addition to SM-102, Cayman sells many other RUO-grade products that are used by academic and industrial scientists worldwide in the preclinical exploration of novel therapies to address diseases such as cancer, immune disorders, inflammation, diabetes, and infectious diseases.

APIs used for commercial pharmaceutical manufacturing adhere to strict guidelines under FDA-regulated Good Manufacture Practice (GMP) protocols to ensure their safety for human and veterinary use. Chemicals under the same name can have differing designations such as grade or formulation that are defined by their manufacturing protocols and intended use. This designation is indicated on the Safety Data Sheet (SDS) included with each Cayman product.

SDSs are required to present the content and hazards of each ingredient in a shipped chemical product. The SDS for Cayman’s SM-102 (Item # 33474) accurately represents that the mixture of chemicals in the product are 90% ethanol (a common solvent) and 10% SM-102. While it is a common solvent, ethanol has several known serious hazards, which have been included on Cayman’s SDS. Neither the National Institute for Occupational Safety and Health (NIOSH), Registry of Toxic Effects of Chemical Substances (RTECS), or the European Chemicals Agency (ECHA) Classification and Labelling Inventory list any hazards associated with SM-102.